cobas® CT/NG

Proven efficiency, giving you the freedom to do more

With STI rates on the rise, cobas® CT/NG provides a solution to meet the growing demand for CT/NG Testing, delivering exceptional assay performance, providing broader information for improved patient care decisions, and enabling simplicity and flexibility to support varying throughput and workflow requirements.

Features and benefits

Exceptional assay performance

  • The Dual-Target approach of cobas® CT/NG of both the genomic and cryptic plasmid DNA of C. trachomatis, ensures inclusion of nvCT strains for a highly sensitive test.
  • The use of two sets of primers targeting the highly conserved direct repeat region (DR9) and a conserved sequence variant amplify and detect both wild type and variant versions of N. gonorrhoeae.

     

Simplicity and flexibility to meet varying throughput and workflow requirements

  • Highest throughput molecular test for CT/NG on the market.
  • Onboard capacity of up to 5,670 CT/NG Tests with onboard stability of 90 days.
  • Continuous loading of samples with no pre-sorting required for mixed test requests.
  • Simultaneous processing of multiple tests from the same patient sample.
  • Full automation and process control of all STI tests onto a single platform including LDTs­­.

Chlamydia trachomatis

RMD_Chlamydia trachomatis

Neisseria gonorrhoea

RMD_ Neisseria gonorrhoea
Intended use

The cobas® CT/NG for use on the cobas® 6800/8800 Systems is an automated, qualitative in vitro nucleic diagnostic test, that utilizes real-time polymerase chain reaction (PCR), for the direct detection of Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (NG) DNA in male and female urine, clinician-instructed self-collected vaginal swab specimens, clinician-collected vaginal swab specimens, endocervical swab specimens, all collected in cobas® PCR Media (Roche Molecular Systems, Inc.), and cervical specimens collected in PreservCyt® Solution. This test is intended as an aid in the diagnosis of chlamydial and gonococcal disease in both symptomatic and asymptomatic individuals.

Registration status

CE-IVD

Package inserts

Access package inserts through your country’s Roche Diagnostics Website.

Related systems

RMD_cobas_6800_280x184
cobas® 6800 System

Transform your testing experience for IVD applications—just 2 simple user interactions per run and up to 8 hours of walk-away time..

Learn more
RMD_cobas_8800_280x184
cobas® 8800 System

Unparalleled performance with minimal operator interaction revolutionizes the future of highthroughput applications.

Learn more